Integrated Pharmaceuticals Shareholders Elect Sally Johnson-Chin to the Board of Directors

FITCHBURG, Mass., Nov 12, 2004 /PRNewswire-FirstCall via COMTEX/ -- Integrated Pharmaceuticals Inc. (IntePharm) (OTC: INTP.PK) today announced the election of Sally Johnson-Chin to the Board of Directors at the Company's 2004 Annual Meeting. Ms. Johnson-Chin is Vice President of Finance and Administration of Oeschle International Advisors, LLC, a Boston based financial services management company. She has been with Oeschle International since 1999. Ms. Johnson-Chin received an MBA from Babson College, earned her CPA in Massachusetts in 1980, and has been an auditor for Ernst & Young, LLP.

"Ms. Johnson-Chin brings financial expertise to the Board, which will be very helpful as we enter the next phase of our development. She has been an advisor to the Company since 2002, and has been very helpful in providing insights into the finance and capital markets. She was one of the earliest investors in the Company, and we are grateful for her continued support and service," said Chinmay Chatterjee, Ph.D., chairman and CEO of IntePharm. "We look forward to the value she will provide to our Board of Directors."

At the 2004 Annual Meeting, the shareholders also approved an increases in the number of shares of common stock covered by the Company's 2002 Stock Plan from 1.2 million to 1.6 million; and approved an amended and restated Articles of Incorporation.

About the Company

IntePharm is a development stage biotechnology company that is dedicated to the manufacturing of pharmaceuticals, specialty compounds and chemicals for the pharmaceutical, neutraceutical and food industries. Integrated Pharmaceuticals discovers and develops more efficient and cost-effective manufacturing processes, using a comprehensive technology platform that combines metabolic engineering, cellular genetics, advanced bioprocess engineering, and computer simulation science. The company is now making production samples of its portfolio of compounds at its cGMP manufacturing facility in Fitchburg, Massachusetts.

For further information please contact Dr. Chinmay Chatterjee, Integrated Pharmaceuticals, Inc. at (978) 696-0020, or visit http://www.intepharm.com.

Forward-Looking Statements

Certain statements contained in this press release that are not historical facts constitute "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, in general, predict, indicate or imply future results, performance or achievements and generally use words so indicative. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results or performance of the Company and its business to be materially different from that expressed or implied by such forward-looking statements. Included in those factors are the following: our dependence on a limited number of potential customers; limited managerial experience of our executives; possible needs for additional capital; possible delays in product development and delivery schedules; deferred or lost sales because of the complex sales process prevalent in the industries that we seek to serve; increased competitive pressure; and rapid technological changes. Forward-looking statements by their very nature are uncertain. There can be no guarantee that any forward-looking statement will be fulfilled. The Company assumes no obligation to update forward-looking statements to reflect actual results or changes in or additions to the factors affecting such forward- looking statements.

SOURCE Integrated Pharmaceuticals, Inc. Web Site: http://www.intepharm.com

Copyright © 1996-2004 PR Newswire Association LLC. All Rights Reserved. A United Business Media company.